JPH08502497A - 波長特異的感光性ポルファシアニン及び拡大されたポルフィン様化合物及び調製のための方法とその使用 - Google Patents
波長特異的感光性ポルファシアニン及び拡大されたポルフィン様化合物及び調製のための方法とその使用Info
- Publication number
- JPH08502497A JPH08502497A JP6510513A JP51051394A JPH08502497A JP H08502497 A JPH08502497 A JP H08502497A JP 6510513 A JP6510513 A JP 6510513A JP 51051394 A JP51051394 A JP 51051394A JP H08502497 A JPH08502497 A JP H08502497A
- Authority
- JP
- Japan
- Prior art keywords
- compound
- cells
- porfacyanin
- conjugate
- compounds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
- A61K41/0076—PDT with expanded (metallo)porphyrins, i.e. having more than 20 ring atoms, e.g. texaphyrins, sapphyrins, hexaphyrins, pentaphyrins, porphocyanines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
- A61K51/0485—Porphyrins, texaphyrins wherein the nitrogen atoms forming the central ring system complex the radioactive metal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/004—Acyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Radiology & Medical Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.式 のポルフィリンにおいて、R1〜R8が各々、独立した非干渉置換基であり、R9 とR10の各々が独立に−H又は であり、各々Xが独立に非干渉置換基であるポルフイリン。 2.R1〜R8各々及び各Xが、−H、置換もしくは非置換基アルキル、アルケニ ル、アルキニル;置換もしくは非置換基アリール;アルキルもしくはアリールス ルホニル;アルキルもしくはアリールシアノ;ハロゲン;シアノ;ニトロ;アミ ノ;カルボキシ;カルバルコキシ;及びそれらのエステル、アミド及び塩からな る群中より独立に選択される請求項1に記載の化合 物。 3.R9とR10がHである請求項1又は2に記載の化合物。 4.R9及びR10の一方がHであり、もう一方が であり、又はR9とR10の両方が である請求項1又は2に記載の化合物。 5.R1〜R8の各々が独立にエチル又はHである請求項1〜4のいずれか1に記 載の化台物。 6.式Tsm−L−Pcで表されるコンジュゲートであって、 Tsmは標的特異的モイエティを表し、 Pcは400〜850nmの範囲に光の吸収極大をもつポルフアシアニンを表し、 Lは共有結合又は共有結合を通してTsmとPcに結台する架橋剤モイエティを 表すコンジュケート。 7.Tsmが免疫グロブリン叉は免疫グロブリンの断片であり、又は、 ステロイドであり、又は、 糖であり、又は、 T細胞リセプターを含み、及び/又は、 Lが共有結合を表す請求項6に記載のコンジュゲート。 8.少なくとも1つの製薬的に受け入れることのできる賦形剤を含む混合物であ って、請求項1〜5のいずれか1に記載の化合物又は請求項6又は7に記載のコ ンジユゲートを有効量含む特定の細胞又は組織に対し細胞毒性のある製薬的組成 物。 9.標的とされる細胞、組織又はウイルスの代謝を害し、破壊をもたらす方法に おける請求項1〜5のいずれか1に記載の化合物または請求項6または7に記載 のコンジュゲートの使用であって、前記細胞、組織又はウイルスに有効量の前記 化台物又はコンジュゲートを投与し、その投与された細胞、組織又はウイルスに 400〜850nmの範囲の波長の光を照射することを含む使用。 10.請求項1〜5のいずれか1に記載の化台物及び常磁性イオンを含む磁気共 鳴イメージング(MRI)コントラスト剤。 11.常磁性イオン要素がガドリニウム(III)またはマンガン(II)である請 求項10に記載の診断用コントラスト剤。 12.病気の組織を検出する方法における請求項10又は11に記載の薬剤の使 用であって、そのような投 与の必要な動物に前記コントラスト剤を投与し、そして動物内でのコントラスト 剤の分布を観察することを含む使用。 13.請求項1〜5のいずれか1に記載の化合物及びテクネチウム、インジウム 、ガリウムからなる群中より選択される放射性同位元素を含むラジオイメージン グ剤。 14.病気の組織を検出する方法における請求項13に記載の薬剤の使用であっ て、そのような投与の必要な動物に前記ラジオイメージング剤を投与し、そして 動物内でのラジオイメージング剤の分布を観察することを含む使用。 15.各Rが非干渉置換基であり、次に示す過程からなる請求項1に記載したポ ルフアシアニンを調製する方法。 (a)粗製産物をつくるため、適当に置換された5,5’−ビスアミノメチル− 2,2’−ジビロメタンに10倍過剰の2,3−ジクロロ−5,6−ジシアノ− 1,4−ベンゾキノンを加え、 (b)アルミナカラム上でクロマトグラフィーにより粗製産物を精製し、そして 、 (c)精製されたポルフアシアニンを乾燥状態になるまで溶媒を蒸発させる。 16.次に示す過程を含む請求項1に記載したポルフ アシアニンを調製する方法。 (a)乾燥メタノール中で適当に置換されたジホルミル−2,2’−ジビロメタ ンを懸濁し、 (b)過程(a)の溶液を通して、アンモニアガスを泡立て通気し、 (c)過程(b)の産物を少なくとも72時間の間、少なくとも60℃で加熱し 、 (d)過程(c)の産物を0℃まで冷やし、 (e)アルミナカラム上でクロマトグラフィーにより粗製産物を精製し、そして 、 (f)精製されたポルファシアニンを乾燥状態になるまで溶媒を蒸発させる。
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US07/968,966 | 1992-10-30 | ||
US07/968,966 US5405957A (en) | 1992-10-30 | 1992-10-30 | Wavelength-specific photosensitive compounds and expanded porphyrin-like compounds and methods of use |
US968,966 | 1993-06-15 | ||
US077,789 | 1993-06-15 | ||
US08/077,789 | 1993-06-15 | ||
US08/077,789 US5512675A (en) | 1992-10-30 | 1993-06-15 | Methods for preparing porphyrin-like compounds |
PCT/CA1993/000470 WO1994010172A1 (en) | 1992-10-30 | 1993-10-29 | Wavelength-specific photosensitive porphacyanine and expanded porphyrin-like compounds and methods for preparation and use thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH08502497A true JPH08502497A (ja) | 1996-03-19 |
JP3108438B2 JP3108438B2 (ja) | 2000-11-13 |
Family
ID=25515006
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP06510513A Expired - Fee Related JP3108438B2 (ja) | 1992-10-30 | 1993-10-29 | 波長特異的感光性ポルファシアニン、拡大されたポルフィリン様化合物及び調製のための方法とその使用 |
Country Status (12)
Country | Link |
---|---|
US (2) | US5405957A (ja) |
EP (1) | EP0666859A1 (ja) |
JP (1) | JP3108438B2 (ja) |
KR (1) | KR100284928B1 (ja) |
CN (1) | CN1092424A (ja) |
AU (1) | AU683856B2 (ja) |
CA (1) | CA2147509A1 (ja) |
FI (1) | FI951986A (ja) |
NO (1) | NO951635L (ja) |
TW (1) | TW268953B (ja) |
WO (1) | WO1994010172A1 (ja) |
ZA (1) | ZA938108B (ja) |
Families Citing this family (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5599924A (en) * | 1992-08-14 | 1997-02-04 | Trustees Of The University Of Pennsylvania | Electron-deficient porphyrins and processes and intermediates for preparing same |
US5817830A (en) * | 1992-08-14 | 1998-10-06 | Trustees Of The University Of Pennsylvania | Pyrrolic compounds |
US5726304A (en) * | 1992-10-30 | 1998-03-10 | The University Of British Columbia | Porphocyanine and CNC-expanded porphyrins |
US6214876B1 (en) * | 1994-07-21 | 2001-04-10 | Eli Lilly And Company | Indene-1-acetamide sPLA2 inhibitors |
CA2206203A1 (en) * | 1997-05-27 | 1998-11-27 | University Of British Columbia | Photoactivation of endogenous porphyrins for treatment of psoriasis |
US6277337B1 (en) * | 1998-07-21 | 2001-08-21 | Gambro, Inc. | Method and apparatus for inactivation of biological contaminants using photosensitizers |
WO2000023117A1 (en) * | 1998-10-16 | 2000-04-27 | The General Hospital Corporation | Photosensitizer conjugates for targeting intracellular pathogens |
US20020022032A1 (en) * | 1999-04-23 | 2002-02-21 | Curry Patrick Mark | Immuno-adjuvant PDT treatment of metastatic tumors |
US6376483B1 (en) | 1999-05-27 | 2002-04-23 | Miravant Pharmaceuticals, Inc. | Bacteriochlorins and bacteriopurpurins useful as photoselective compounds for photodynamic therapy and a process for their production |
US8215314B2 (en) * | 2000-02-11 | 2012-07-10 | The General Hospital Corporation | Photochemical tissue bonding |
US7073510B2 (en) * | 2000-02-11 | 2006-07-11 | The General Hospital Corporation | Photochemical tissue bonding |
CA2399414A1 (en) * | 2000-02-11 | 2001-08-16 | The General Hospital Corporation | Photochemical tissue bonding |
CA2408332C (en) | 2000-05-08 | 2011-02-15 | The University Of British Columbia | Supports for photosensitizer formulations |
WO2001085212A2 (en) * | 2000-05-08 | 2001-11-15 | The University Of British Columbia | Drug delivery systems for photodynamic therapy |
WO2002038566A2 (en) * | 2000-11-10 | 2002-05-16 | The University Of Akron | Carbene porphyrins and carbene porphyrinoids for use in medical diagnosis and treatment |
WO2002096366A2 (en) * | 2001-05-31 | 2002-12-05 | Miravant Pharmaceuticals, Inc. | Metallotetrapyrrolic photosensitizing agents for use in photodynamic therapy |
ATE442861T1 (de) * | 2003-03-07 | 2009-10-15 | Univ Texas | Gegen antikörper gerichtete photodynamische therapie |
US8519146B2 (en) * | 2004-09-07 | 2013-08-27 | The University Of Akron | Metal complexes of N-heterocyclic carbenes as antibiotics |
CN101955494A (zh) * | 2003-09-05 | 2011-01-26 | 阿克伦大学 | 用作放射性药物和抗生素的n-杂环卡宾的金属配合物 |
AU2005280639A1 (en) * | 2004-02-17 | 2006-03-09 | Billy T. Fowler | Methods, compositions, and apparatuses for forming macrocyclic compounds |
US20060171845A1 (en) * | 2005-01-31 | 2006-08-03 | Dakota Technologies, Inc. | Sensors for measuring analytes |
EP2129788B1 (en) | 2007-01-30 | 2014-09-03 | SETA BioMedicals, LLC | Luminescent compounds |
US8782681B2 (en) | 2007-03-08 | 2014-07-15 | The Nielsen Company (Us), Llc | Method and system for rating media and events in media based on physiological data |
HRP20070111B1 (hr) * | 2007-03-16 | 2014-11-21 | Institut Ruđer Bošković | Derivati adamantanskih dipirometana, metoda priprave i upotreba za detekciju aniona |
CA2688412A1 (en) * | 2007-05-31 | 2008-12-11 | The University Of Akron | Metal complexes incorporated within biodegradable nanoparticles and their use |
CA2693587A1 (en) * | 2007-07-23 | 2009-01-29 | The University Of Akron | Metal complexes incorporated within biodegradable nanoparticles and their use |
US20110070153A1 (en) * | 2008-08-13 | 2011-03-24 | Searete, Llc, A Limited Liability Corporation Of The State Of Delaware | Artificial cells |
AU2009327266B2 (en) | 2008-12-16 | 2015-10-29 | Valeant Pharmaceuticals International, Inc. | Combination of photodynamic therapy and anti-VEGF agents in the treatment of unwanted choroidal neovasculature |
US8829020B2 (en) | 2009-07-16 | 2014-09-09 | Mallinckrodt Llc | Compounds and compositions for use in phototherapy and in treatment of ocular neovascular disease and cancers |
HUE034119T2 (en) | 2010-02-04 | 2018-01-29 | Morphotek Inc | Chlorotoxin polypeptides and conjugates and their use |
WO2013003507A1 (en) | 2011-06-27 | 2013-01-03 | Morphotek, Inc. | Multifunctional agents |
EP2771688B1 (en) | 2011-10-25 | 2018-09-26 | Memorial Sloan-Kettering Cancer Center | Free psa antibodies as diagnostics, prognostics and therapeutics for prostate cancer |
CN102680704B (zh) * | 2012-04-28 | 2015-02-11 | 广州鸿琪光学仪器科技有限公司 | 一种快速定量检测微量白蛋白的免疫荧光试纸条组件及其制成的检测卡组件和制备方法 |
CN102680703B (zh) * | 2012-04-28 | 2014-12-17 | 广州鸿琪光学仪器科技有限公司 | 一种快速定量检测肌红蛋白的免疫荧光试纸条组件及其制成的检测卡组件和制备方法 |
CN102680702B (zh) * | 2012-04-28 | 2014-12-17 | 广州鸿琪光学仪器科技有限公司 | 一种快速定量检测c-反应蛋白的免疫荧光试纸条组件、及其制成的检测卡组件和制备方法 |
AU2013334102B2 (en) | 2012-10-26 | 2018-08-16 | Memorial Sloan-Kettering Cancer Center | Modulators of resistant androgen receptor |
AU2014370182B2 (en) | 2013-12-23 | 2021-07-15 | Memorial Sloan-Kettering Cancer Center | Methods and compositions for treating cancer using peptide nucleic acid-based agents |
CN109575036B (zh) * | 2018-12-11 | 2020-09-22 | 怀化学院 | 金属血卟啉双醚二酯类化合物,催化剂及其制备方法以及环己烷催化氧化方法 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5051415A (en) * | 1986-01-02 | 1991-09-24 | The University Of Toledo | Production and use of purpurins, chlorins and purpurin- and chlorin-containing compositions |
DE3635820A1 (de) * | 1986-10-22 | 1988-04-28 | Basf Ag | Vinyloge porphyrine |
US4935498A (en) * | 1989-03-06 | 1990-06-19 | Board Of Regents, The University Of Texas System | Expanded porphyrins: large porphyrin-like tripyrroledimethine-derived macrocycles |
US5162509A (en) * | 1989-03-06 | 1992-11-10 | Board Of Regents, The University Of Texas System | Process for preparing expanded porphyrins: large porphyrin-like tripyrroledimethine-derived macrocycles |
US5124449A (en) * | 1990-09-20 | 1992-06-23 | Basf Aktiengesellschaft | Azaporphyrin derivatives |
-
1992
- 1992-10-30 US US07/968,966 patent/US5405957A/en not_active Expired - Lifetime
-
1993
- 1993-06-15 US US08/077,789 patent/US5512675A/en not_active Expired - Lifetime
- 1993-10-29 CA CA002147509A patent/CA2147509A1/en not_active Abandoned
- 1993-10-29 EP EP93924466A patent/EP0666859A1/en not_active Withdrawn
- 1993-10-29 ZA ZA938108A patent/ZA938108B/xx unknown
- 1993-10-29 CN CN93120727A patent/CN1092424A/zh active Pending
- 1993-10-29 JP JP06510513A patent/JP3108438B2/ja not_active Expired - Fee Related
- 1993-10-29 WO PCT/CA1993/000470 patent/WO1994010172A1/en not_active Application Discontinuation
- 1993-10-29 AU AU54143/94A patent/AU683856B2/en not_active Ceased
- 1993-10-29 KR KR1019950701688A patent/KR100284928B1/ko not_active IP Right Cessation
-
1994
- 1994-01-13 TW TW083100289A patent/TW268953B/zh active
-
1995
- 1995-04-26 FI FI951986A patent/FI951986A/fi not_active Application Discontinuation
- 1995-04-28 NO NO951635A patent/NO951635L/no unknown
Also Published As
Publication number | Publication date |
---|---|
CN1092424A (zh) | 1994-09-21 |
EP0666859A1 (en) | 1995-08-16 |
AU683856B2 (en) | 1997-11-27 |
AU5414394A (en) | 1994-05-24 |
KR950704321A (ko) | 1995-11-17 |
FI951986A (fi) | 1995-06-21 |
NO951635L (no) | 1995-06-09 |
ZA938108B (en) | 1995-05-02 |
TW268953B (ja) | 1996-01-21 |
KR100284928B1 (ko) | 2001-03-15 |
US5512675A (en) | 1996-04-30 |
US5405957A (en) | 1995-04-11 |
CA2147509A1 (en) | 1994-05-11 |
FI951986A0 (fi) | 1995-04-26 |
NO951635D0 (no) | 1995-04-28 |
JP3108438B2 (ja) | 2000-11-13 |
WO1994010172A1 (en) | 1994-05-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH08502497A (ja) | 波長特異的感光性ポルファシアニン及び拡大されたポルフィン様化合物及び調製のための方法とその使用 | |
AU638675B2 (en) | Wavelength-specific cytotoxic agents | |
JP2835294B2 (ja) | 波長特異的な細胞毒性を有する試薬 | |
US5095030A (en) | Wavelength-specific cytotoxic agents | |
EP0423195B1 (en) | Purified hematoporphyrin trimers useful in photodynamic therapy | |
US5171749A (en) | Wavelength-specific cytotoxic agents | |
US5399583A (en) | Method of treating skin diseases | |
WO1991014456A2 (en) | Improved compositions for photodynamic therapy | |
US5308608A (en) | Photosensitizing Diels-Alder porphyrin derivatives | |
US5149708A (en) | Photosensitizing Diels-Alder porphyrin derivatives | |
US5726304A (en) | Porphocyanine and CNC-expanded porphyrins | |
US4961920A (en) | Phototherapeutic monovinyl and divinyl ether-linked dimers | |
AU641658B2 (en) | Photosensitizing diels-alder porphyrin derivatives | |
MXPA96004956A (en) | Porfocianin and porfirinas extended with | |
JPH0780887B2 (ja) | 波長特異的細胞毒性試薬 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20070908 Year of fee payment: 7 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20080908 Year of fee payment: 8 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20080908 Year of fee payment: 8 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090908 Year of fee payment: 9 |
|
LAPS | Cancellation because of no payment of annual fees |